Non-invasive liver screening for patients with liver disease
Non-invasive Liver Screening Using FibroScan Device for Liver Disease Patients for the Steatosis/Fibrosis Database
This study is testing a non-invasive device to measure liver stiffness and fat in patients with liver disease to help gather information for future research and clinical trials.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | State University of New York at Buffalo Academic / other |
| Locations | 1 site (Buffalo, New York) |
| Trial ID | NCT02897908 on ClinicalTrials.gov |
What this trial studies
This observational study aims to create a comprehensive database of individuals with varying levels of hepatic fibrosis and different types of liver diseases. Using the FibroScan device, researchers will measure liver stiffness and fat content to assess the extent of liver fibrosis and steatosis. Patients with known or suspected liver disease will be approached for voluntary FibroScan measurements, and their demographic, medical, and clinical data will be collected for future research purposes. The goal is to facilitate the identification of potential subjects for upcoming clinical trials.
Who should consider this trial
Good fit: Ideal candidates include individuals with known or suspected risk factors for liver steatosis or fibrosis, as well as those diagnosed with conditions like Non-Alcoholic Steatohepatitis (NASH).
Not a fit: Patients under 18 years of age, pregnant women, and those with severe obesity (BMI ≥40) are unlikely to benefit from this study.
Why it matters
Potential benefit: If successful, this study could enhance the understanding and management of liver diseases, leading to better-targeted treatments for patients.
How similar studies have performed: Other studies utilizing non-invasive liver screening methods have shown promise, indicating that this approach may be effective.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Subjects with known, or suspected risk factors for steatosis (fat) or hepatic fibrosis * Subjects who have been previously diagnosed with Non-Alcoholic Steatohepatitis (NASH) but who do not have current steatosis (fat) or fibrosis scoring * Subjects who have other known liver diseases ie: HCV Exclusion Criteria: * Patients less than 18 years of age * Pregnancy * Patients that do not want to be contacted for consideration in future research studies. * Patients diagnosed with ascites or peritoneal dialysis * Body mass index (BMI) ≥40
Where this trial is running
Buffalo, New York
- Conventus Medical Office Building — Buffalo, New York, United States (Recruiting)
Study contacts
- Study coordinator: Ajay Chaudhuri, MD
- Email: achaudhu@buffalo.edu
- Phone: 716-907-1916
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.